PEOPLE - Changes at Calypte Biomedical (US):
This article was originally published in Clinica
Executive Summary
HIV-1 antibody test producer Calypte Biomedical (Alameda, California) has appointed Richard George as president and CEO and Richard Van Maanen as vice-president of operations. Dr George has 35 years of experience with the Centers for Disease Control and Prevention (CDC) and Mr Van Maanen has been involved with HIV diagnostics industry for 19 years. Calypte Biomedical has also announced the departure of Jay Oyakawa, who has resigned from his position as president and COO.
You may also be interested in...
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.